Cue生物制药 CUE 深 沪
等待开盘 07-03 09:30:00 美东时间
27.26
-1.080
-3.81%
华盛通- 最 高29.5466
- 今 开29.00
- 成交量 1.43万股
- 最 低 27.25
- 昨 收 28.34
- 总市值 1.15亿
- 52周最高 41.42
- 市盈率 静 --
- 换手率 0.34%
- 52周最低 4.971
- 委 比 91.33%
- 总股本 420.03万
- 历史最高 950.70
- 量 比 0.23
- 振 幅 8.10%
- 历史最低 4.971
- 每 手 1
- 风险率 7.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
Cue Biopharma announced the transition of its board, with four independent directors resigning, and the appointment of Daniel Camardo and Viola Meehan. Camardo, a former CEO with a track record of successful drug launches, and Meehan, a seasoned CFO with expertise in strategic finance, will bring critical experience to support the company's growth and late-stage clinical capabilities. The company emphasized their contributions to advancing transf...
06-02 20:05
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies for immunological disorders, announced that its CEO, Shao-Lee Lin, will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 3:10 p.m. EDT in New York City. A live audio webcast and replay of the presentation will be available through Cue Biopharma’s Investor Relations website for 90 days. Cue Biopharma is a...
05-21 20:05
Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.10) by 1100 percent. This is a 78.18 percent increase over losses of $(4.95) per share from the
05-15 05:24
Watching Cue Biopharma; Fugazi Research Issues Report On Co. Titled "$CUE: Reverse Splits, PIPE Dilution, and the Illusion of Recovery"
https://www.fugaziresearch.com/p/cue-reverse-splits-pipe-dilution
05-11 21:42
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cue Biopharma granted inducement equity awards to seven new employees, including its new CEO Shao-Lee Lin, under its 2026 Inducement Stock Incentive Plan. Dr. Lin received stock options for 655,074 shares and 327,537 restricted stock units, with options vesting monthly over four years. Other employees received options for 518,599 shares and 327,534 restricted stock units, with options vesting quarterly over four years. The company focuses on deve...
05-07 23:07
世之源核心管线UB-221海外权益由关联方Ascendant Health授权予Cue Biopharma，达成最高6.915亿美元总付款的许可合作
（来源：申联生物） 近日，申联生物子公司扬州世之源（Genesis Life Sciences）之关联方Ascendant Health Sciences ...
05-06 10:57
Why Is Cue Biopharma Stock Up Today?
Cue Biopharma stock was up after the company announced a $30 million private pl...
05-01 20:53
Market-Moving News for May 1st
AAPL: 4% | Apple shares are trading higher after the company reported better-than-expected Q2 financial results, issued Q3 sales guidance above estimates, announced a $100 billion share buyback, and raised its
05-01 19:16
Cue Biopharma Enters Into Exclusive License Agreement With Ascendant Health To Develop, Manufacture And Commercialize Ascendant-221, Phase 2 Clinical Stage Anti-IgE Monoclonal Antibody For Treatment Of Allergic Diseases
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseasesCue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results
05-01 04:28
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma appoints Shao-Lee Lin, M.D., Ph.D., as CEO and President. Dr. Lin brings over 25 years of biopharmaceutical leadership experience, including successful IPOs and regulatory approvals. She will lead the advancement of CUE-401, a novel therapeutic for autoimmune diseases, and expand the clinical pipeline. Cue Biopharma focuses on developing innovative therapies targeting T cells to address autoimmune and inflammatory conditions.
04-30 20:05
